Sanofi (SNY.US) BTK inhibitor receives domestic approval for market launch
智通财经2026/09/03 07:21Show original
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
Smart Finance APP reports that on September 3, the official website of the National Medical Products Administration (NMPA) showed that Sanofi (SNY.US)'s BTK inhibitor rilzabrutinib tablets have been approved for market launch. They are indicated for adult patients with persistent or chronic primary immune thrombocytopenia (ITP) who have responded poorly or are intolerant to previous treatments such as glucocorticoids and immunoglobulins.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bernstein raises Broadcom's target price to $575
智通财经•2026/09/03 09:31
Bernstein raises Dell's target price to $650
智通财经•2026/09/03 09:31
Russia’s oil and gas fiscal revenue in August reached 424 billion rubles
智通财经•2026/09/03 09:31
